Non-Allergic Rhinitis

TITLE: Non-Allergic Rhinitis
SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology
DATE: December 16, 2009
RESIDENT PHYSICIAN: Leonel Martinez, MD
FACULTY PHYSICIAN: Patricia Maeso, MD
SERIES EDITORS: Francis B. Quinn, Jr., MD
ARCHIVIST: Melinda Stoner Qui= nn, MS(ICS)

"This material was prepared by resident physicians in partial fulfillment of educational requirements established for the Postgraduate Training Program of the UTMB Department of Otolaryngology/Head= and Neck Surgery and was not intended for clinical use in its present form. It = was prepared for the purpose of stimulating group discussion in a conference setting. No warranties, either express or implied, are made with respect to= its accuracy, completeness, or timeliness. The material does not necessarily reflect the current or past opinions of members of the UTMB faculty and sho= uld not be used for purposes of diagnosis or treatment without consulting appropriate literature sources and informed professional opinion."

Introduction

Rhinitis in general is defined as two or more nasal symptoms of: = nasal congestion, rhinorrhea, sneezing or impairment of smell for more than 1 hr a day. There are different form= s of rhinitis, generally divided into three main categories 1) Infectious rhinit= is 2) Allergic rhinitis 3) Non-Allergic rhinitis. Allergic rhinitis is defined as immunologic nasal response, primary mediated by immunoglobulin E (IgE).

Non-allergic rhinitis is defined as rhinitis sym= ptoms in the absence of identifiable allergy, structure abnormality or sinus disease. There have been many= terms to describe non-allergic rhinitis which include vasomotor rhinitis, vascular rhinitis, perennial, chronic and noninfectious perennial rhinitis, among others.

A quick review of nasal function is warranted. Nasal function includes temperature regulation, olfaction, humidification, filtration and protection. The nasal mucosal lining contains = IgA, proteins and enzymes which help protect from infections. Also, nasal cilia propel the matter toward the natural ostia at a frequency of 10-15 beats per minute, which ca= uses a mucous flow at rate of 2.5 to 7.5 ml per minute.

A review of the epidemiology shows that up to 10= % of the US population is affected by rhinitis.= That is 58 million Americans with allergic rhinitis and another 19 million with non-allergic rhinitis. However, in the population that present to an ENT clinic, 50% of rhinitis patients are diagnosed with allergic rhinitis and the other 50% are diagnosed with non-allergic rhinitis.

Potential problems that arise from non-allergic rhinitis (NAR) are similar to allergic rhinitis, which include development = of sinusitis, Eustachian tube dysfunction, chronic otitis media and anosmia. This leads to decreased work productivity and frequent doctor visits.&n= bsp; Also, the treatment leads to side effects of drowsiness, epistaxis a= nd nasal dryness.

CAUSES

In this talk, we will discuss the major causes o= f non-allergic rhinitis. They are broken dow= n into the following:

Occupational,= Drug induced, Rhinitis Medicatmentosa, NARES, Hormonal, Idiopathic or Vasomotor = and Mimicker.

Occupational

Arises from airborne agents at a patient’s workplace. These agents do no= t act through immune mediated systems, but are an irritant to the nasal mucosa and cause hyper responsive reactions. They trigger both the Olfactory nerve and the Trigeminal nerve that senses burning and irritation by airborne chemicals.

There have been over 205 different chemical iden= tified as irritants. They include cigarette smoke, solvents like chlorine, metal salts, latex, glues and wood dust. These patients usually present with a concurrent occupational asthma.

For diagnosis, we use primarily history and nasal provocation with stimuli. Abo= ut 70% of patients improve with symptoms when triggers are avoided.

Drug Induced Rhinitis

There are a variety of medications that can cause rhinitis when administered either orally or topically. These drugs can be divided into tw= o main groups as pharmacologic or aspiring hypersensitivity.

Here is that include many of the drugs that are = common causes rhinitis.

= · = Cocaine

= · = Topical nasal decongestants

= · = phosphodiesterase type-5 inhibitors (PDE-5)--Sildenafi

= · = Alpha-adrenoceptor antagonists

= · = Reserpine

= · = Hydralazine

= · = Angiotensin-converting enzyme inhibitors

= · = Beta-blockers

= · = Methyldopa

= · = Guanethidine

= · = Phentolamine

= · = Oral contraceptives

= · = Non steroidal anti-inflammatory medications

= · = Aspirin

= · = Psychotropic agents

= · = Thioridazine

= · = Chlordiazepoxide

= · = Chlorpromazine

= · = Amitriptyline

= · = Perphenazine

= · = Alprazolam

Many common antihypertensive medication and psychiatric medications cause rhinitis.&nb= sp; These are infrequent but predicable side effects. They usually lead to congestion, b= ut PND and watery secretions can be other symptoms.

PDE-5 inhibitors like Sildenafil (Viagra) cause = allergic rhinitis by inducing engorgement of the nasal mucosa including the turbinat= es.

Intolerance to ASA or NSAIDS is unpredictable. However, they predominately cause rhinorrhea. ASA rhinitis may = be a part of the ASA triad of hyperplasic rhinosinusitis, nasal polyps and asthma.

Rhinitis Medicamentosa

Rhinitis medicamentosa (RM) is a condition that = caused by overuse of topical nasal steroids. Also known as rebound or chemical rhinitis, the incidence is somewhe= re between 1-9% of non-allergic rhinitis and it is more common in younger adul= ts and pregnant women.

To understand the cause of RM, we must first loo= k at some of the basic science behind the nasal mucosa. The mucosa is innervated by sympat= hetic fiber that release norepinephrine, which stimulate alpha 1 and alpha 2 rece= ptors. This in turns causes vasoconstrict= ion.

The sympathomimetic amines and imidazoline deriv= atives (phenylephrin and oxymetazoline, respectively) both produce vasoconstrictio= n by endogenous release of norepinephrine.

The problem arises with prolonged use. This leads to reduced production of norepinephrine in the presynapes and decreased sensitivity of the alpha receptors in the postsynapes, which in turn requires higher doses for short= er acting time. This cycle of ex= cess dose use and decrease symptomatic relief will lead to worsening of the orig= inal symptoms.

The risk of RM is greatest after 10 days use of medications. Treatment includ= es gradual stopping of decongestant with introduction of topical corticosteroid. This will lea= d to a temporary increase in symptoms and patents should be warned beforehand of t= his and to not restart the original medication. Patients should be off the medicat= ion for 3 months before starting any other surgical or medical treatment for the original nasal disease.

NARES

NARES (non-allergic rhinitis with eosinophilia syndrome) is another non-alle= rgic entity that is defined as rhinitis without allergic cause but has 20-25% eosinioph= ils seen on nasal smears. As with= the other NAR disease, there is lack of allergy by skin test or IgE antibodies. Prevalence is 13-= 33% of NAR.

NARES etiology is unknown. However, it is believed to be asso= ciated with the ASA triad as NARES patients tend to develop asthma and nasal polyps later in life and they tend to have abnormal prostaglandin metabolism. And yet, eosinophilic counts are elevated in 20% of the nasal smears in the general population and not every= one with eosinophilias have symptom of rhinitis.

Recent studies by Powe et al (2001) show that NA= RES is a local IgE mediated response that does not result in a systemic response.<= span style=3D'mso-spacerun:yes'> They found that 50% of non-allergic rhinitis pt that had a negative skin prick test were found to have positive result to nasal allergy challenge. Therefore, skin prick tes negative pt with eosinophilia may require allergen challenge nasally before diagnosis of non-allergic rhinitis. This is important to know, because= NARES is a subset of non-allergic rhinitis who responds better to nasal corticosteroids than other non-allergic rhinitis groups.

Hormonal Rhinitis

Hormonal rhinitis (HR) is defined as rhinitis du= ring period so known hormonal imbalance. Estrogens are known to affect the autonomic nervous system by increa= sing a host of factor including parasympathetics, acetyl choline transferase, and acytycholine content, and also increase inhibition of sympathetic system. Therefore, the most common causes = are pregnancy, menstruation, puberty and exogenous estrogen. With pregnancy, HR usually manifes= ts in the second month and will continue throughout pregnancy.

Hypothyroidism is also known to cause hormonal rhinitis. In hypothyroidism, increase TSH release causes edema of the turbinates. Nasal congestion and rhinorrhea ar= e the most common symptoms of RH.

Idiopathic rhinitis

Next we come to Idiopathic rhinitis (IR). This is also known as vasomotor rh= initis and is characterized by nasal blockage and rhinorrhea, with some sneezing a= nd pruritis. Etiology is unclear= , with failed attempts to differentiate by hyperactivity to histamine, methacholin= e, cold air or capsaicin. IR is = solely diagnosed by patient complaints and therefore a diagnosis of exclusion.

The exclusion criteria include: having positive = skin test, smoking, nasal polyps, pregnancy, medications affecting nasal functio= n, and good response to nasal steroids. Pt who have a good response to nasal steroids tend to have NARES.

IR is not believed to be caused by inflammation.= IR patients have no significant in= crease in mucosal lymphocytes, antigen presenting cells, eosinophils, macrophages, mast cells or IgE positive cells compared to controls. And studies have shown a reduction= in immunocompetent cells in the mucosa of IR pt after treatment with nasal steroids did not reduce nasal complaints.

Others

Finally we come to the last group of NAR, the ot= her category. There are a number = of conditions that can produce the same signs and symptoms of rhinitis. These include structural condition= s like deviated septum, nasal tumors, enlarged adenoids or turbinates, and atrophic rhinitis. One must also look = for mimicker like Wegener’s, sarcoidosis, and polychondritis.

Diagnosis

To provide an accurate diagnosis, one must always start with complete history and physical exam.

Here are some pertinent questions to ask with th= e history:

What are your nasal an sinus symptoms and do they include discharge, congestion, PND, sneezing, itching?
Do you have environmental allergies, undergone skin testing, or been trea= ted for allergies?
Are there certain situations, environment in which symptoms are worse like home, work, indoors, outdoors, times of the year or day?
What is your work, are there exposures to chemicals? Do your symptoms begin with medications or do any medications help your symptoms?
Do you have asthma, allergy to aspirin, or any sinus polyps?
Have you undergone any sinus surgeries?

With the physical exam, one should do a n= asal endoscopy. Boggy, edematous m= ucosa suggest noninfections, while inflammation and purulent discharge from middle meatus suggests infection.

Treatment

The key to treatment is patient education. Teach patient to avoid triggers, h= ave them change their environment, change their medication. If these are not feasible, then me= dical therapy is the next course of action.

Immunologic therapy ahs no benefit to non-allerg= ic rhinitis and therefore it is important to distinguish the disease before considering immunotherapy. Nasal lavage h= as been shown to have minor decongestion benefits and improves mucocilliary function.

Topical nasal steroids have been used widely for= use with NAR. Fluticasone, budeso= nide an beclomthasone are the only ones approved by FDA for use in NAR. However, efficacy is inconsistent = and use must be for a minimum of 6 wks. With the exception of NARES, topical steroids do not provide the same relief as they do with allergic rhinitis.

Antihistamines have given us inconsistent results. Histamine release is= the main pathophysiology for allergic rhinitis and therefore, not a good consideration for NAR. Azelas= tin intranasal have been proven efficacious for all forms of NAR, including Idiopathic rhinitis. It is an H1 receptor antagonist that also inhibits synthesis of leukotrienes, kinins, cytokines = and free radicals. The exact mech= anism behind its relief is unknown.

Anticholinergic drugs also have their place in treatment. Ipratropium bromid= e has been shown to be effective with rhinorrhea symptoms. The strength used is 0.03% with 2 = sprays TID initially. The dose is sl= owly lowered to one spray BID as maintenance.&n= bsp;

Mast cell stabilizers such as cromolyn have been= shown to have no benefit with non-allergic rhinitis. There have been no studies that ha= ve looked at leukotriene modifies in the treatment of non-allergic rhinitis.

Capsaicin has been shown to be of benefit to idiopathic rhinitis. This is = the main chemical with in hot peppers. This substance is known to activate C-fiber in the nose which is responsible for pain. With repeated applicati= on of capsaicin, a desensitization and degeneration of c-fibers occur. A five dose treatment of high dosa= ges at 1 hr intervals has been shown to work as well as five high dose treatments = over 2 wks. Up to 75% of patients = will show long lasting relief. The= re are lower dose capsaicin formulation nasal sprays that are available OTC at pharmacies that can be used in higher frequencies.

Surgery is used only for failed medical treatment. Although nasal pol= yps and septal deviation do not cause NAR, they can cause problems with medicat= ions reaching its desired goal and therefore should be corrected.

Silver nitrate has been studied as therapy. Given topically, it has been shown= to down regulate stimuli of the mucosa. Clinical trials show improvement over placebo and anosmia was shown = to be rare side effect. A 20% so= lution was applied by cotton tip for 1 minute once a wk for 5 wks.

Vidian Neurectomy has been demonstrated as treat= ment modality. Since 1961, it has = been used successfully to relieve rhinorrhea.&n= bsp; Initially done transantral, it has been moved to transnasally by endoscopy. Efficacy is up to = 88%.

Turbinate reduction has also been beneficial. In a randomized control trial of 3= 82 pt, with 6 yr follow up, a sub-mucus resection with lateral displacement has be= en found to be better in term of efficacy to turbinectomy, laser, cryotherapy,= or electrocautery.

Recently, Ikeda et all (2006) has shown benefit = to a combined vidian neurectomy with inferior turbinate resection for treatment = of chronic rhinitis.

Follow up

Follow up is key for patient with non-allergic rhinitis. In a recent study by Rondon et al (2009), non-allergic rhinitis pt shown previously to have no sensitization to rest were found to sensitized to allergens on follow up. As many as 24% of the pt were foun= d to develop sensitization. This s= uggest that sensitization may appear later in the coarse of rhinitis disease. Other studies have shown differenc= es in allergy test dosages that may impact diagnosis.

Conclusion

In conclusion, non-allergic rhinitis is mainly a diagnosis of exclusion of IgE causes. NAR is seen in up to 50% of ENT pt with rhinitis. H+P is important step in diagnosis= as are allergy testing.

Treatment includes avoidance, medication changes= , and monitor of hormones. Topical steroids and Topical H-1 receptor antagonist Azelastine are FDA approved for NAR. Anticholinergic medicati= ons and capsaisin have been proven beneficial for treatment, while mast cell stabilizers and leukotriene modifiers have not.

References

3D"*" 1.= Smith TL: Vasomotor rhinitis is not a wastebasket diagnosis. Arch Otolaryngol Head Neck Surg 2003; 129:584<= /p>

3D"*" 2. Settipane RA, Lieberman P: Update on non-allergic rhinitis. &nbs= p; Ann Allergy Asthma Immunol 2001; 86:494.<= /p>

3D"*" 3. Settipane RA. Demographics and epidemiology of allergic and non-allergic rhinitis. Allergy Asthma Proc 2001;22:185–189

3D"*" 4. Bachert C. Persistent rhinitis—allergic or non-allergic? Allergy 2004; 59[Suppl 76]:11–15

3D"*" 5. Scadding GK. Non-allergic rhinitis: diagnosis and management. Curr Opin All= ergy Clin Immunol 2001;1:15–20

3D"*" 6. Jones AS. Autonomic reflexes and non-allergic rhinitis. Allergy 1997; 52:14= -19

3D"*" 7= . Blom HM, Van Rijswijk JV, Garrelds IM, et al. Intranasal capsaicin is efficaciou= s in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study: Clin Exp Allergy 1997; 27:796-80

3D"*" 8. Dockhorn R, Aaronson D, Bronsky E, et al. Ipratropium bromide nasal spray 0= .03% and beclomethasone spray alone and in combination for the treatment of rhin= itis and perennial rhinitis. Ann Allergy Asthma Immunol 1999; 82:349-359

3D"*" 9. Erhan E, Kulahji I, Kandemir O, et al. Comparison of topical silver nitrate= and flunisolide treatment in patients with idiopathic non-allergic rhinitis. To= kai J Exp Med 1995; 21:103-111

3D"*" 1= 0.Rondo ́n C, Don ̃a I, Torres MJ, Campo P, Blanca M. Evolution of patien= ts with non- allergic rhinitis supports conversion to allergic rhinitis. J All= ergy Clin Immunol 2009;123:1098-102

3D"*" 1= 1.Sander I, Fleischer C, Meurer U, Br€uning T, Raulf-Heimsoth M. Allergen cont= ent of grass pollen preparations for skin prick testing and sublingual immunotherapy. Al- lergy 2009 Apr 6. [Epub ahead of print] DOI:10.1111/j.1398-9995.2009.02040.x.

3D"*" 1= 2. Powe DG, Huskisson RS, Carney AS, et al. Evidence for an inflammatory patho= physiology in &= nbsp; idiopathic &= nbsp; rhinitis. Clin Exp Allergy 2001;&nbs= p; 31:864 – 872.

3D"*" 1= 3.Rondon C, Romero JJ, Lopez S, et al. Local IgE production and positive nasal provocation test in patients with persistent non-allergic rhinitis. J Aller= gy Clin Immunol 2007; 119:899–905

3D"*" 1= 4. Bachert C. Persistent rhinitis – allergic or non-allergic? Allergy 20= 04; 59(Suppl. 76):11–15.

3D"*" 1= 5. Slavin RG. Occupational rhinitis. Ann Allergy Asthma Immunol 1999;83(6 Pt 2):597–60

3D"*" 1= 6. Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebou= nd swelling, tolerance, and nasal hyperreactivity. Rhinology 1996;34:9– = 13.

3D"*" 1= 7. Graf P. Rhinitis medicamentosa: as- pects of pathophysiology and treat- men= t. Allergy 1997;52(Suppl. 40):28– 34.

3D"*" 1= 8. Incaudo G, Schatz M. Rhinosinusitis associated with endocrine conditions: hypothyroidism and pregnancy. In: Schatz M, Settipane GA, eds. Nasal manifestations of systemic diseases. Providence, RI, USA: Oceanside, 1991; = 54.

3D"*" 1= 9. Jacobs RL, Freedman PM, Boswell RN. Non-allergic rhinitis with eosino- phil= ia (NARES syndrome). Clinical and immunologic presentation. J Al- lergy Clin Immunol 1981;67:253–262

3D"*" 2= 0. Moneret-Vautrin DA, Hsieh V, Wayoff M, Guyot JL, Mouton C, Maria Y. Non-all= ergic rhinitis with eosinophilia syndrome a precursor of the triad: na- sal polyposis, intrinsic asthma, and intolerance to aspirin. Ann Allergy 1990;64:513–518.

3D"*" 2= 1. Blom HM, Godthelp T, Fokkens WF, KleinJan A, Mulder PGM, Rijntjes E. The ef= fect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with a non-allergic non- infect= ious perennial rhinitis. J Allergy Clin Immunol 1997;100:739–747.